Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549855 | 0.99 | LMNA (0.54) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL15584548 | 0.86 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL30500926 | 0.86 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL25393509 | 0.84 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL10152341 | 0.83 | CTSL (0.51) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL3647693 | 0.83 | CTSL (0.53) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL4861409 | 0.83 | CTSL (0.53) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL29845981 | 0.82 | CTSS (0.58) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL16590476 | 0.81 | FKBP1A (0.60) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5601416 | 0.81 | CTSS (0.57) | CTSLCTSBCTSSLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024246713-A1 | A PROCESS FOR THE PREPARATION OF CDK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD (IN) | 2024-12-05 | — | — | WO | disclosed |
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | G1 THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708337-B2 | Synthesis of 1,4-diazaspiro[5.5]undecan-3-one | NDC1, SDC1, SDC2 | CTSL 2364/4885CTSB 3921/4885CTSS 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.